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INTRODUCTION
According to National Cattlemen's Association data, there are approximately 35 million
beef cows and 10 million dairy cows in the United States.  Combining pre-calving, pre-weaning,
yearling, breeding bulls and replacement heifer vaccination opportunities to utilize Clostridial
immunization programs, it is estimated that well in excess of 100 million doses of various
Clostridial containing products are used each year.  Knowing which products stimulate
satisfactory antibody levels and their duration of response is an essential part of making informed
recommendations to producers for controlling disease. Presently, non-industry, controlled field
studies assessing Clostridial products are not available.
Specifically, Clostridium perfringens Type C is a common cause of neonatal calf
diarrhea.  Although histopathological diagnoses of this disease are made, these cases are
frequently difficult to confirm.  They are often referred to as sudden/unknown death in calves. 
From 18 veterinary diagnostic laboratories across the United States contributing to the
USDA:APHIS:VS DxMONITOR (summer, 1992), 237 suspected cases of Clostridium
perfringens Types C were tested during the period January 1, 1992 to March 31, 1992, but only
22 cases were confirmed.  As such, Veterinary Clinicians must rely on gross necropsy results and
frequently make recommendations with limited confirmatory information. Anecdotal information
from several veterinary clinicians suggests that the incidence of these non-confirmed diagnoses
diminished greatly with the use of Clostridium perfringens C&D products prophylactically.
Various opinions abound as to whether the best response to controlling Clostridium
perfringens Type C or sudden death in young beef calves is achieved with the use of toxoid,
antitoxin, or both, and whether an acceptable response is achieved by administration at birth,
two-weeks, or at two-months-of-age.  Lack of definitive information regarding optimum
protection afforded by the use of these products and their timing leads to possible ineffective use. 
This, therefore, results in increased cost of the production by both product purchase and labor,
and possible increased tissue damage as observed by several Beef Quality Assurance Programs
using 7-way Clostridial products. 
EXPERIMENTAL DESIGN
Approximately 240 beef calves born unassisted to first-calf heifers, located at two
different ranch sites, (synchronized at breeding and due to calve within 3 days of each other)
were divided into four groups.  After each calf nursed colostrum naturally, it received either an
appropriate dosage of 7-way Clostridial toxoid subcutaneously using the "tented" technique in
the cervical region; 10 cc of Clostridial antitoxin in the same manner; both injections; or 10 cc of
saline as a control.  All dams were boostered with Clostridium perfringens Types C&D toxoid or
Scourgard 3-K-C and C&D toxoid 2-4 weeks prior to the due date.  Calves were born within 7-
10 days of each other.  Calves born to dams boostered pre-calving with C&D toxoid and
randomly assigned to the toxoid treatment group at birth were given 7-way toxoid (post-
colostrally).  Calves born to dams boostered pre-calving with Scourgard 3-K-C and C&D toxoid
and randomly assigned to the toxoid treatment group at birth were given C&D toxoid at birth
(post-colostrally).  All calves in all groups were boostered at branding (80-90 days-of-age) with
7-way Clostridial toxoid.
Blood samples were taken (pre-injection) within 48 hours of birth; at branding; and at
weaning (6-7 months).  Assays using ELISA techniques were performed to determine the
antibody response levels for each treatment group.
RESULTS
Clostridium perfringens Type C antibody levels in beef calves born to dams boostered
pre-calving with C&D toxoid were not different at either of the sampling periods.  Antibody
levels in calves administered 7-way toxoid, 10 cc C&D antitoxin, 7-way toxoid and 10 cc
antitoxin, or saline at birth did not differ (p>0.05) when measured at branding or weaning.  The
initial antibody levels at birth, post-colostrally, were similar for all treatment groups prior to the
treatment administration.  The administration of 7-way toxoid at branding did not result in
differing levels at weaning.  (Figure 1)
Clostridium perfringens Type C antibody levels in beef calves born to dams boostered
pre-calving with Scourgard 3-K-C and C&D toxoid were not different at branding.  Antibody
levels in calves administered C&D toxoid, 10 cc C&D antitoxin, C&D toxoid and 10 cc
antitoxin, or saline at birth did not differ (p>0.01) when measured at branding.  Antibody levels
in calves receiving C&D toxoid and the calves receiving C&D antitoxin did differ at the weaning
period (p<0.01).  The initial antibody levels at birth, post-colostrally, were similar for all
treatment groups prior to the treatment administration.  (Figure 2)
CONCLUSIONS
1. Administering  C&D toxoid, 10 cc C&D antitoxin, both, or saline at birth to beef calves
did not alter Clostridium perfringens Type C antibody levels as measured at branding
and/or weaning.
2. Pre-calving vaccinations in first-calf beef heifers result in different Clostridium
perfringens Type C antibody levels at birth (post-colostrally).


